The reduced production of IL-2 in patients with SLE is most likely the underlying cause of pathogenically significant abnormalities, including reduction of counterinflammatory regulatory T cell subset counts and the number of cytotoxic lymphocytes [145]. Here, IL2 is linked to systemic lupus erythematosus.